Primary Sclerosing Cholangitis clinical trials at UC Health
4 research studies open to eligible people
A Study of Experimental PLN-74809 in Cholangitis and Suspected Liver Fibrosis
open to eligible people ages 18-75
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis
at UC Davis
A Study of Experimental Sulfasalazine for Primary Sclerosing Cholangitis (inflammation and scarring of the bile ducts)
“This research study hopes to find out if experimental treatment with sulfasalazine can help people with PSC.”
open to eligible people ages 15-80
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.
at UC Davis
A Study of the Safety and Effectiveness of Experimental Cilofexor for Primary Sclerosing Cholangitis (scarring of bile ducts)
open to eligible people ages 18-75
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
at UC Davis UCSF
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
open to eligible people ages 18 years and up
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
at UC Davis
Last updated: